Distinguished in Cellulitis

Dr. Godson I. Oguchi

Infectious Disease
955 Town Ctr Dr, Suite 100, 
Orange City, FL 
Accepting New Patients
Offers Telehealth
Distinguished in Cellulitis
955 Town Ctr Dr, Suite 100, 
Orange City, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Godson Oguchi is an Infectious Disease provider in Orange City, Florida. Dr. Oguchi is rated as a Distinguished provider by MediFind in the treatment of Cellulitis. His top areas of expertise are Cellulitis, Osteomyelitis, COVID-19, and Lymphangitis. Dr. Oguchi is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Infectious Disease
Licenses
Internal Medicine in FL
Hospital Affiliations
Adventhealth Fish Memorial
Adventhealth Deland
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Florida Health
  • HMO
  • POS
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 20 Less Insurance Carriers -

Locations

955 Town Ctr Dr, Suite 100, Orange City, FL 32763

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A 2-Part, 2-Arm, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
A 2-Part, 2-Arm, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
Enrollment Status: Terminated
Publish Date: October 08, 2024
Intervention Type: Drug
Study Drug: Niclosamide
Study Phase: Phase 2
A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae
A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae
Enrollment Status: Completed
Publish Date: May 30, 2024
Intervention Type: Drug
Study Drugs: Gepotidacin, Ceftriaxone, Azithromycin
Study Phase: Phase 3
An Open-label, Non-comparator, Multicenter Study to Describe the Pharmacokinetics (PK), Pharmacodynamics (PD; Viral Load) and Safety Following a Single Intravenous or Intramuscular Dose of Sotrovimab in Pediatric Participants With Mild to Moderate COVID-19 at High Risk of Disease Progression
An Open-label, Non-comparator, Multicenter Study to Describe the Pharmacokinetics (PK), Pharmacodynamics (PD; Viral Load) and Safety Following a Single Intravenous or Intramuscular Dose of Sotrovimab in Pediatric Participants With Mild to Moderate COVID-19 at High Risk of Disease Progression
Enrollment Status: Terminated
Publish Date: January 03, 2024
Intervention Type: Biological
Study Drug: Sotrovimab
Study Phase: Phase 2
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: June 22, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
View 5 Less Clinical Trials

3 Total Publications

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
Journal: The New England journal of medicine
Published: December 22, 2021
Similar Doctors
Distinguished in Cellulitis
Dr. Ivan I. Soosaipillai
Infectious Disease
Distinguished in Cellulitis
Dr. Ivan I. Soosaipillai
Infectious Disease

Infectious Diseases Associates Of North Central Florida LLC

3306 Sw 26th Ave, Suite 104, 
Ocala, FL 
 (55.8 miles away)
352-622-2020
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ivan Soosaipillai is an Infectious Disease provider in Ocala, Florida. Dr. Soosaipillai is rated as a Distinguished provider by MediFind in the treatment of Cellulitis. His top areas of expertise are Osteomyelitis, Cellulitis, Lymphangitis, Osteomyelitis in Children, and Tissue Biopsy. Dr. Soosaipillai is currently accepting new patients.

Distinguished in Cellulitis
Dr. Negia E. Lalane-Del
Infectious Disease
Distinguished in Cellulitis
Dr. Negia E. Lalane-Del
Infectious Disease

Florida Health Care LLC

929 N Hwy 441, Suite 102, 
Lady Lake, FL 
 (37.6 miles away)
352-350-2474
Languages Spoken:
English
See accepted insurances

Negia Lalane-Del is an Infectious Disease provider in Lady Lake, Florida. Dr. Lalane-Del is rated as an Advanced provider by MediFind in the treatment of Cellulitis. Her top areas of expertise are Cellulitis, Osteomyelitis, Lymphangitis, and Pneumonia.

Distinguished in Cellulitis
Dr. Ukonu O. Ejie
Infectious Disease
Distinguished in Cellulitis
Dr. Ukonu O. Ejie
Infectious Disease

Infectious Diseases Of Mid-Florida, PA

290 Clyde Morris Blvd, Suite D2, 
Ormond Beach, FL 
 (27.1 miles away)
386-265-1021
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ukonu Ejie is an Infectious Disease provider in Ormond Beach, Florida. Dr. Ejie is rated as an Advanced provider by MediFind in the treatment of Cellulitis. His top areas of expertise are Cellulitis, Sepsis, Pneumonia, and Osteomyelitis. Dr. Ejie is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Oguchi's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile